Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
GDRX
GDRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GDRX News
Market Sentiment Shift Creates Opportunities
Feb 06 2026
Benzinga
GoodRx Becomes Major Integration Partner for Pfizer on TrumpRx
Feb 06 2026
seekingalpha
Amazon Enters GLP-1 Drug Market, Competing with Pharma Giants
Feb 06 2026
Fool
GoodRx Partners with TrumpRx to Launch Drug Discounts
Feb 06 2026
Newsfilter
GoodRx Partners with TrumpRx to Launch Drug Discounts
Feb 06 2026
Businesswire
GoodRx Achieves HITRUST i1 Certification for Cybersecurity Leadership
Feb 02 2026
Newsfilter
Trump's Venezuela Initiative Is Driving Up Oil Stocks: The Raid Was the Simple Step.
Jan 06 2026
Barron's
Novo Nordisk Launches Wegovy Pill with 17% Average Weight Loss Efficacy
Jan 05 2026
Benzinga
Novo Nordisk's Wegovy Pill Now Available in Pharmacies: A New Development in the Weight-Loss Competition.
Jan 05 2026
Barron's
GoodRx Launches Wegovy Oral Medication at $149 Monthly Cash Price
Jan 05 2026
Newsfilter
Tempus AI Nears Profitability While Reporting GAAP Losses
Dec 19 2025
NASDAQ.COM
Wegovy Prices Are Decreasing, Yet They Remain 'Significantly Varied' and Confusing
Dec 04 2025
MarketWatch
HIMS vs. GDRX: Which Health Stock Presents More Potential for Growth?
Nov 28 2025
NASDAQ.COM
Novo Nordisk Focuses on Cost-Effectiveness in Response to Increasing Competition
Nov 17 2025
Benzinga
GoodRx Introduces $39 Monthly Weight Loss Telemedicine Subscription, Offers Competitive Introductory Cash Price of $199 Monthly for Ozempic® and Wegovy®
Nov 17 2025
Newsfilter
Novo Nordisk reduces monthly prices for Wegovy and Ozempic to $349 for consumers.
Nov 17 2025
CNBC
Show More News
